These interconnected mechanisms—insulin resistance, chronic inflammation, and mitochondrial dysfunction—collectively contribute to muscle degradation in individuals with high CMI, highlighting the need for targeted interventions for sarcopenia. This evidence concerns the gene INS and sarcopenia.